CHICAGO, January 10, 2011
Baird Venture Partners (BVP), the U.S.-based venture fund of Baird Private Equity, announced today that Interlace Medical (Interlace), a Baird Venture Partners III portfolio company, has been sold to Hologic for $125 million with additional earn-out payments over the next two years. This acquisition will allow Interlace to accelerate the adoption of its products through the Hologic distribution network. In June 2009, Interlace raised $20.5 million in Series C financing from investors that included BVP, Spray Venture Partners, New Leaf Venture Partners, HLM Venture Partners, Hambrecht & Quist Capital Management LLC, and Aperture Venture Partners.
Based in Framingham, Mass., Interlace is a medical device company dedicated to providing novel solutions within the women’s health sector. Interlace developed and commercialized the MyoSure™ system, an easy-to-use, minimally invasive treatment to remove intrauterine fibroids and polyps. Fibroids are a common cause of abnormal uterine bleeding, which afflicts 5 million women in the United States. The MyoSure system’s allows physicians the flexibility to conduct procedures in either an operating room or office setting.
"We were able to partner with a great management team at Interlace to develop a much needed product serving the women’s health sector," said Michael Liang, BVP Partner. "The acquisition of Interlace by Hologic provides a nice early return for our BVP III investors, and further validates our strategy of proactively identifying healthcare companies that are capital efficient and can be an attractive acquisition for trade buyers."
"Baird Venture Partners has been a great partner for us," said Bill Gruber, Interlace President and CEO. "Their lead role in our latest financing and active role on the Board accelerated our growth initiatives and ability to get the MyoSure product into the marketplace. Their involvement was invaluable to help us enter our next phase of growth as part of Hologic." Baird Venture Partners raised BVP III, a $170 million fund, in 2008. The Fund has made eight investments to date.
About Baird Venture Partners
Baird Venture Partners, the U.S.-based venture capital fund of Baird Private Equity, makes venture capital investments in early and expansion stage business services and life sciences companies. Baird Venture Partners leverages its in-depth sector knowledge, experienced investment team and network of relationships to serve as a value-added partner for its portfolio companies. For more information, please visit www.bairdventurepartners.com.
About Baird Private Equity
Baird Private Equity, the global private equity group of Robert W. Baird & Co. (Baird), makes venture capital, growth equity and buyout investments in smaller, high potential companies in the United States through Baird Venture Partners and Baird Capital Partners, in China through Baird Capital Partners Asia, and in Europe through Baird Capital Partners Europe. Baird Private Equity has a global team of investment and operations professionals in nine offices across the United States, Europe and Asia, including a team of operating professionals in Asia. Baird Private Equity and its affiliates have raised and managed over $2.7 billion in capital and invested in more than 240 companies since the 1980s. For more information, please visit www.bairdprivateequity.com.